DPX 101
Alternative Names: DPX-101Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Damona Pharmaceuticals
- Class Antipsychotics; Nootropics; Small molecules
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cognition disorders; Schizophrenia
Most Recent Events
- 04 Nov 2024 Preclinical trials in Cognition disorders in Canada (PO) before November 2024 (Damona Pharmaceuticals pipeline, November 2024)
- 04 Nov 2024 Preclinical trials in Schizophrenia in Canada (PO) before November 2024 (Damona Pharmaceuticals pipeline, November 2024)
- 04 Nov 2024 US FDA approves IND application for DPX 101 to initiate phase I clinical trial in healthy participants